Top Tweets for #SWENOTECA

almost 2 years ago

🌟Advancing Biomarker Science in Testicular Cancer: Insights from the #SWENOTECA-MIR Study 🌟 @OncoAlert 🔬 Key Messages: miR-371a-3p as a Biomarker: 🔸️Proven as a highly specific marker for seminoma patients undergoing primary retroperitoneal lymph node dissection (RPLND). 🔸️Demonstrates a sensitivity of 74% and specificity of 100%, outperforming conventional markers. Clinical Relevance: 🔸️Offers potential for avoiding overtreatment by identifying viable tumors pre-chemotherapy. 🔸️Limited utility in nonseminoma and postchemotherapy contexts. Study Highlights: 🔸️Largest prospective cohort to date (114 patients) using digital droplet PCR for miR-371a-3p analysis. 🔸️Provides population-based data with rigorous optimism-corrected performance metrics. 🌟 Findings: Seminomas: 🔸️miR-371a-3p levels significantly decline post-RPLND, indicating its reliability in tracking tumor viability. 🔸️Serves as a non-invasive, radiation-free alternative to conventional diagnostics. Nonseminomas and Teratomas: 🔸️miR-371a-3p showed low sensitivity and no significant postoperative changes. 🔸️Conventional markers may still hold value in these subgroups. Future Directions: 🔸️Integration with artificial intelligence and radiomics could enhance predictive capabilities. 🔸️Further validation needed to standardize thresholds and broaden clinical applications. 📊 Implications for Patient Care: 🔸️Enables tailored treatment plans by distinguishing patients who genuinely require RPLND. 🔸️Reduces risks of long-term morbidity associated with unnecessary surgeries. #TesticularCancer #PrecisionOncology #Biomarkers #ClinicalResearch #OncologyInnovation #CancerCare https://t.co/wRDlDkZ2PX

nataliagandur's tweet photo. 🌟Advancing Biomarker Science in Testicular Cancer: Insights from the #SWENOTECA-MIR Study 🌟
@OncoAlert
🔬 Key Messages:

miR-371a-3p as a Biomarker:
🔸️Proven as a highly specific marker for seminoma patients undergoing primary retroperitoneal lymph node dissection (RPLND).
🔸️Demonstrates a sensitivity of 74% and specificity of 100%, outperforming conventional markers.

Clinical Relevance:
🔸️Offers potential for avoiding overtreatment by identifying viable tumors pre-chemotherapy.
🔸️Limited utility in nonseminoma and postchemotherapy contexts.

Study Highlights:
🔸️Largest prospective cohort to date (114 patients) using digital droplet PCR for miR-371a-3p analysis.
🔸️Provides population-based data with rigorous optimism-corrected performance metrics.

🌟 Findings:

Seminomas:
🔸️miR-371a-3p levels significantly decline post-RPLND, indicating its reliability in tracking tumor viability.
🔸️Serves as a non-invasive, radiation-free alternative to conventional diagnostics.

Nonseminomas and Teratomas:
🔸️miR-371a-3p showed low sensitivity and no significant postoperative changes.
🔸️Conventional markers may still hold value in these subgroups.

Future Directions:
🔸️Integration with artificial intelligence and radiomics could enhance predictive capabilities.
🔸️Further validation needed to standardize thresholds and broaden clinical applications.

📊 Implications for Patient Care:
🔸️Enables tailored treatment plans by distinguishing patients who genuinely require RPLND.
🔸️Reduces risks of long-term morbidity associated with unnecessary surgeries.
#TesticularCancer #PrecisionOncology #Biomarkers #ClinicalResearch #OncologyInnovation #CancerCare
https://t.co/wRDlDkZ2PX

Torgrim Tandstad @torgrimtandstad

about 2 years ago

Results of primary RPLND in low-volume metastatic seminomatous testicular cancer, treated in spezialized centers as standard treatment according to #SWENOTECA X. Potential reduced long-term morbidity and mortality compared to primary radiotherapy or chemotherapy.

torgrimtandstad's tweet photo. Results of primary RPLND in low-volume metastatic seminomatous testicular cancer, treated in spezialized centers as standard treatment according to #SWENOTECA X. Potential reduced long-term morbidity and mortality compared to primary radiotherapy or chemotherapy. https://t.co/Ol05mLdP1V

212

UroToday.com

@urotoday

about 3 years ago

Primary RPLND in #seminoma stage IIA-IIC ≤3cm: combined results of the #SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne. Presented by @torgrimtandstad @StOlavshospital. #ASCO23 written covrage by @zklaassen_md @GACancerCenter > https://t.co/2d1x2B3wbz @ASCO

urotoday's tweet photo. Primary RPLND in #seminoma stage IIA-IIC ≤3cm: combined results of the #SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne. Presented by @torgrimtandstad @StOlavshospital. #ASCO23 written covrage by @zklaassen_md @GACancerCenter > https://t.co/2d1x2B3wbz @ASCO https://t.co/Bxz1TNNGAr

Yüksel Ürün

@DrYukselUrun

about 4 years ago

Late relapses in testicular cancer: Low rate of recurrence after 5 years! "Centralization of treatment, adherence to guidelines, prospective registration of patients, and subsequent reporting of results are key" Torgrim Tandstad, MD, PhD #swenoteca @ASCO #ASCO22 @OncoAlert

Top Tweets for #SWENOTECA

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users